AVANIR to Present at the NewsMakers in the Biotech Industry Conference

ALISO VIEJO, Calif., September 9, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that the Company will present at the NewsMakers in the Biotech Industry Conference on Wednesday, September 16th at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) at the Millennium Broadway Hotel and Conference Center in New York City. The NewsMakers in the Biotech Industry Conference provides the opportunity for participating companies to present to highly qualified financial professionals, including institutional investors and banking institutions. Presenting companies are handpicked based on objective selection criteria, such as investor validation, unpartnered assets and upcoming value-shaping milestones.

A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the presentation at the NewsMakers in the Biotech Industry Conference will be available on the Company's website.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.

To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0

AVANIR Investor Contacts
Eric Benevich or Brenna Mullen, 949-389-6700
ir@avanir.com

Sep 09, 2009